SUBSCRIBE
SUBSCRIBE
News   Policy

Hospira, Inc. Says FDA Suspends Oxaliplatin Approval

August 17, 2009 | 
1 min read

Bookmark and Share

Reuters -- Hospira Inc on Friday said U.S. regulators had suspended its approval, received only three days earlier, to sell a generic injectable formulation of Sanofi-Aventis’ colon cancer drug Eloxatin.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Intercept’s Troubled Drug Ocaliva Linked to ‘Serious Liver Injury’: FDA
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Donald Trump behind a podium
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former CytoDyn Officials Found Guilty of Securities Fraud
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac